Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR): Resultados clínicos del uso de risperidona inyectable de liberación prolongada a dos años de seguimiento

Imagem de Miniatura
Arquivos
art_LOUZA_Electronic_Schizophrenia_Treatment_Adherence_Registry_in_Latin_America_2013.PDF (351.79 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2013
SciELO
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEX PSIQUIATRIA
Autores
APIQUIAN, Rogelio
CORDOBA, Rodrigo
FRESAN, Ana
Citação
SALUD MENTAL, v.36, n.1, p.19-26, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Schizophrenia is a chronic psychiatric disorder associated to high healthcare costs mainly driven by inpatient care. Lack of adherence to antipsychotic treatment is a common reason for relapse and rehospitalization leading to poor prognosis and global functional impairment of patients. Risperidone long-acting injection (RLAI) has demonstrated its efficacy in treating symptoms of schizophrenia and offers the potential to improve adherence to treatment. Objective To determine clinical and functional efficacy of RLAI and use of health resources (eg., hospitalizations in a 2-year follow up study among patients with schizophrenia from Latin America. Method The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is an Observational study of patients who start treatment with RLAI. Data from patients recruited in Mexico, Colombia and Brazil were collected retrospectively for one year prior to baseline; at baseline and every three months for 24 Months. Hospitalization rates and treatment regime were registered. Efficacy was assessed using the Clinical Global Impression of Illness-Severity Scale (CGI-S), while the Global Assessment of Functioning (GAF) and the Personal and Social Performance (PSP) were used for the evaluation of functioning. Results Seventy-three patients completed the two-year follow-up. The proportion of patients hospitalized declined from 16.4% before treatment to after 2 years of treatment with RLAI. Only 2.7% discontinued the treatment due to lack of efficacy. Significant improvements were reported in illness severity as well-as in global functioning assessed by the CGI.S; GAF and PSP scales, respectively. Discussion Our results give further support of the efficacy of RLAI for the treatment of schizophrenia. Additional to symptom severity reduction and functional recovery, improved treatment adherence and reduced hospitalization rates were observed with the use of RLAI. In a real world clinical setting, RLAI offer an effective long-term treatment for patients with schizophrenia, with a lower use of healthcare resources.
Palavras-chave
Risperidone long-acting injection, schizophrenia, Latin America, treatment adherence
URI
https://observatorio.fm.usp.br/handle/OPI/4562
Referências
  1. American Psychiatric Association, 1994, DIAGN STAT MAN MENT
  2. Apiquian R, 2009, SCHIZOPHR RES, V112, P181, DOI 10.1016/j.schres.2009.03.028
  3. Apiquian Rogelio, 2010, Neuropsychiatr Dis Treat, V7, P19, DOI 10.2147/NDT.S15911
  4. Bech P, 1993, ACTA PSYCHIAT SCAND, V87, P16
  5. Becker MA, 2007, ADM POLICY MENT HLTH, V34, P307, DOI 10.1007/s10488-006-0108-5
  6. Boaz TL, 2011, J CLIN PSYCHIAT, V72, P1079, DOI 10.4088/JCP.09m05348yel
  7. Cabello Rangel Héctor, 2011, Salud Ment, V34, P95
  8. Carswell C, 2010, CLIN DRUG INVEST, V30, P777, DOI 10.2165/11537680-000000000-00000
  9. Chang CL, 2010, PSYCHIAT RES, V180, P16, DOI 10.1016/j.psychres.2009.11.005
  10. Chue P, 2005, EUR NEUROPSYCHOPHARM, V15, P111, DOI 10.1016/j.euroneuro.2004.07.003
  11. Damen Joep, 2008, Appl Health Econ Health Policy, V6, P189, DOI 10.2165/00148365-200806040-00002
  12. Emsley R, 2008, J CLIN PSYCHOPHARM, V28, P210, DOI 10.1097/JCP.0b013e318167269d
  13. Emsley R, 2008, INT CLIN PSYCHOPHARM, V23, P325, DOI 10.1097/YIC.0b013e32830c2042
  14. ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766
  15. Ereshefsky Larry, 2005, Drugs R D, V6, P129, DOI 10.2165/00126839-200506030-00001
  16. Fenton WS, 1997, SCHIZOPHRENIA BULL, V23, P637
  17. Fleischhacker WW, 2003, J CLIN PSYCHIAT, V64, P1250
  18. Gianfrancesco FD, 2006, PSYCHIAT RES, V144, P177, DOI 10.1016/j.psychres.2006.02.006
  19. Hofer A, 2000, J CLIN PSYCHOPHARM, V20, P699, DOI 10.1097/00004714-200012000-00019
  20. Kane JM, 2003, AM J PSYCHIAT, V160, P1125, DOI 10.1176/appi.ajp.160.6.1125
  21. Keith SJ, 2004, PSYCHIAT SERV, V55, P997, DOI 10.1176/appi.ps.55.9.997
  22. Knapp M, 2004, SCHIZOPHRENIA BULL, V30, P279
  23. Lacro JP, 2002, J CLIN PSYCHIAT, V63, P892
  24. Lambert T, 2011, ANN GEN PSYCHIATR, V10, DOI 10.1186/1744-859X-10-10
  25. Lang K, 2010, PSYCHIAT SERV, V61, P1239, DOI 10.1176/appi.ps.61.12.1239
  26. Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688
  27. Lieberman JA, 2011, AM J PSYCHIAT, V168, P770, DOI 10.1176/appi.ajp.2011.11010039
  28. Lieberman Jeffrey A, 2007, J Clin Psychiatry, V68, pe04
  29. Lindenmayer Jean-Pierre, 2006, J Psychiatr Pract, V12, P55, DOI 10.1097/00131746-200601000-00009
  30. Liu-Seifert H, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-21
  31. Llorca PM, 2008, PSYCHIAT RES, V161, P235, DOI 10.1016/j.psychres.2007.07.012
  32. Marcus SC, 2008, SCHIZOPHRENIA BULL, V34, P173, DOI 10.1093/schbul/sbm061
  33. Morosini PL, 2000, ACTA PSYCHIAT SCAND, V101, P323, DOI 10.1111/j.1600-0447.2000.tb10933.x
  34. Olfson M, 2007, SCHIZOPHRENIA BULL, V33, P1379, DOI 10.1093/schbul/sbm033
  35. Olivares JM, 2009, CURR MED RES OPIN, V25, P2197, DOI 10.1185/03007990903149306
  36. Olivares JM, 2009, EUR PSYCHIAT, V24, P287, DOI 10.1016/j.eurpsy.2008.12.002
  37. Olivares José M, 2008, Appl Health Econ Health Policy, V6, P41, DOI 10.2165/00148365-200806010-00004
  38. Parellada E, 2010, INT CLIN PSYCHOPHARM, V25, P149, DOI 10.1097/YIC.0b013e328336c93f
  39. Perkins DO, 2002, J CLIN PSYCHIAT, V63, P1121
  40. Peuskens J, 2010, CURR MED RES OPIN, V26, P501, DOI 10.1185/03007990903488670
  41. Rabinowitz J, 2011, J CLIN PSYCHOPHARM, V31, P75, DOI 10.1097/JCP.0b013e31820568c6
  42. Rummel-Kluge C, 2008, AUST NZ J PSYCHIAT, V42, P382, DOI 10.1080/00048670801961107
  43. Schmauss M, 2007, INT CLIN PSYCHOPHARM, V22, P85, DOI 10.1097/YIC.0b013e3280119ddb
  44. Sun SX, 2007, CURR MED RES OPIN, V23, P2305, DOI 10.1185/030079907X226050
  45. Svarstad BL, 2001, PSYCHIATR SERV, V52, P805, DOI 10.1176/appi.ps.52.6.805
  46. Taylor M, 2008, J PSYCHOPHARMACOL, V22, P128, DOI 10.1177/0269881107084068
  47. Thornley B, 1998, BRIT MED J, V317, P1181
  48. Valenstein M, 2004, SCHIZOPHRENIA BULL, V30, P255
  49. Velligan DI, 2003, PSYCHIAT SERV, V54, P665, DOI 10.1176/appi.ps.54.5.665
  50. West JC, 2008, SCHIZOPHRENIA BULL, V34, P995, DOI 10.1093/schbul/sbm137
  51. Willis M, 2010, EUR J HEALTH ECON, V11, P585, DOI 10.1007/s10198-009-0215-9
  52. World Health Organization, 2006, DIS CONTR PRIOR REL

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq